JGC
ELGX

J. Goldman & Co’s Endologix Inc ELGX Stock Holding History

J. Goldman & Co’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-7,500
Closed -$996K – 361
2013
Q2 		$996K Buy
+7,500
New +$1.06M 0.1% 184

Other funds holding ELGX

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

J. Goldman & Co's ELGX Position: Q3 2013 in Review

J. Goldman & Co sold out of Endologix Inc (ELGX) in Q3 2013, closing a stake of 7,500 shares — an estimated $996K sold.

J. Goldman & Co first reported a position in ELGX in Q2 2013 and held it in 1 quarter. The position peaked at $996K in Q2 2013. 135 funds tracked by Wall St. Rank hold ELGX as of Q3 2013.

  • J. Goldman & Co reported no remaining Endologix Inc position as of Q3 2013 after selling out during the quarter.
  • J. Goldman & Co sold 7,500 Endologix Inc shares in Q3 2013, an estimated $996K.
  • J. Goldman & Co first reported a position in Endologix Inc in Q2 2013 and held it in 1 quarter.
  • J. Goldman & Co's Endologix Inc position peaked at $996K in Q2 2013.
  • 135 funds tracked by Wall St. Rank held Endologix Inc as of Q3 2013.

Based on J. Goldman & Co's 13F filing for Q3 2013, filed 14 Nov 2013.